Fluoro-polyhydroxy indolizidine compound, pharmaceutically acceptable salt and synthetic method thereof, glycosidase inhibitor and application of glycosidase inhibitor

By designing fluoropolyhydroxyindolecidine compounds and their salts, the problems of low activity and poor fat solubility of choma beans were solved, and efficient inhibition of α-mannosidase and α-rhamnosidase were achieved. and the improvement of pharmacokinetic properties reduces toxic side effects and enhances its application potential in drugs.

CN119060047APending Publication Date: 2024-12-03INST OF CHEM CHINESE ACAD OF SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310649633.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-06-02
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The activity of chomadol is low and the fat solubility is poor, which leads to toxic side effects in clinical applications and is difficult to be used as an effective anti-tumor drug.

Method used

A fluoropolyhydroxyindolecidine compound and its pharmaceutically acceptable salt were designed to increase its inhibitory activity against α-mannosidase and α-rhamnosidase by synthesis, and through the introduction of fluorine Atoms improve their fat solubility.

Benefits of technology

Highly inhibitory activity and selectivity of α-mannosidase and α-rhamnosidase are achieved, while improving the fat solubility of the compounds, reducing toxic side effects, and enhancing their application potential in drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060047A_ABST
    Figure CN119060047A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of glycosidase inhibitors, and discloses a fluorinated polyhydroxy indolizidine compound and pharmaceutically acceptable salt and a synthetic method thereof, and a glycosidase inhibitor and application thereof. The compound has a chemical structure as shown in a formula (1), wherein R1 and R1'are fluorine or hydrogen; wherein R2 is hydrogen or acyl; wherein R3 and R4 are each independently hydrogen, or a combination of R3 and R4 forms a propylidene group; wherein in the formula (1) # imgabs0 #, the spatial configurations of 1, 2, 8 and 8a-site carbon atoms are respectively and independently R or S; the fluoro polyhydroxy indolizidine compound prepared by the invention can be applied to a glycosidase inhibitor, has high inhibition activity of alpha-mannosidase or inhibition activity of alpha-L-rhamnosidase, has high selectivity, and can be applied to the field of medicine preparation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of glycosidase inhibitors, and in particular to a fluorinated polyhydroxyindolizidine compound and a pharmaceutically acceptable salt thereof, a synthesis method thereof, a glycosidase inhibitor and an application thereof. Background Art

[0002] The chemical structure of swainsonine is a polyhydroxyindolizidine iminosugar, which has a strong inhibitory effect on α-mannosidase II. The inhibitory activity IC of swainsonine on α-mannosidase reported in the literature (Yang, LF; Shimadate, Y.; Kato, A.; Li, YX; Jia, YM; Fleet, GWJ; Yu, CY Org. Biomol. Chem. 2020, 18, 999-1011) 50 =0.73μM, and its enantiomer has a good inhibitory effect on α-rhamnosidase. α-Mannosidase is crucial for the late modification of newly synthesized glycoproteins. Swainsonine is a strong α-mannosidase inhibitor, so it can inhibit the biosynthesis of glycoproteins on the surface of tumor cells, thereby inhibiting the metabolism of tumor cells and inducing apoptosis of tumor cells. In addition, swainsonine has the function of immunomodulation. For example, swainsonine can stimulate the immune system of patients with cervical cancer (HPV), stimulate the proliferation of bone marrow cells in the body, improve immunity, and thus enhance the ability to kill tumor cells. Therefore, swainsonine has great application prospects in the treatment of diseases such as cancer, viral infection and fungal infection. At present, swainsonine and its hydrochloride have entered clinical phase II research as alternative drugs for the treatment of cancer, but due to the lipid-water partition coefficient and its irritation to the gastrointestinal tract, the study was terminated in clinical phase II.

[0003] Therefore, structural modification of swainsonine may lead to the discovery of highly active and low-toxic lead compounds. However, the activity and toxicity of compounds obtained by different modification methods may vary greatly. Therefore, it is necessary to find a suitable modification method to prepare swainsonine derivatives with high activity and low toxicity. Summary of the invention

[0004] The purpose of the present invention is to overcome the problems of low activity and poor fat solubility of swainsonine, and to provide a fluoropolyhydroxyindolizidine compound and a pharmaceutically acceptable salt thereof and a synthesis method and a glycosidase inhibitor and an application thereof. The compound has high α-mannosidase inhibitory activity or α-L-rhamnosidase inhibitory activity and is highly selective.

[0005] In order to achieve the above object, the first aspect of the present invention provides a fluorinated polyhydroxy indolizidine compound and a pharmaceutically acceptable salt thereof, wherein the compound has a chemical structure shown in formula (1):

[0006]

[0007] Among them, R 1 is hydrogen and R 1’ is fluorine, or R 1 is fluorine and R 1’ is hydrogen, or R 1 is fluorine and R 1’ For fluorine;

[0008] Among them, R 2 is hydrogen or acyl;

[0009] Among them, R 3 and R 4 are each independently hydrogen, or R 3 and R 4 The combination of forms a propylidene group;

[0010] Wherein, in Formula 1, the stereo configurations of the carbon atoms at positions 1, 2, 8 and 8a are each independently R or S.

[0011] The second aspect of the present invention provides a method for synthesizing fluorinated polyhydroxy indolizidine compounds and pharmaceutically acceptable salts thereof, the method comprising:

[0012] (a) subjecting the compound represented by formula (2) to a first oxidation reaction with a first oxidizing agent to obtain an aldehyde product, and then subjecting the product to an addition reaction with an organometallic reagent in the presence of a medium A to obtain a compound represented by formula (3);

[0013]

[0014] Among them, R 5 is an alkoxycarbonyl group, a benzyloxycarbonyl group, an alkylacyl group, or an arylacyl group; R 3’ and R 4’ The combination of forms a propylidene group;

[0015] (b) subjecting the compound represented by formula (3) to a protection reaction with a protecting group reagent to obtain a compound represented by formula (4), and then subjecting the compound represented by formula (5) to a second oxidation reaction with a second oxidizing reagent;

[0016]

[0017] Among them, R 2’ is an alkoxymethyl group or an acyl group;

[0018] (c) in the presence of a catalyst, subjecting the compound represented by formula (5) to a fluorination reaction with a fluorination agent to obtain a compound represented by formula (6), and then subjecting the compound represented by formula (7) to a cyclization reaction with a reagent I in the presence of a medium B;

[0019]

[0020] (d) subjecting the compound represented by formula (7) to a deprotection reaction with a hydrogen source reagent, reagent I and reagent II to obtain a compound represented by formula (1) and a pharmaceutically acceptable salt thereof;

[0021]

[0022] Among them, R 1 , R 1’ , R 2 , R 3 and R 4 The definition of is the same as that described in the first aspect of the present invention.

[0023] The third aspect of the present invention provides fluorinated polyhydroxyindolizidine compounds and pharmaceutically acceptable salts thereof prepared by the method described in the second aspect of the present invention.

[0024] The fourth aspect of the present invention provides a glycosidase inhibitor, wherein the glycosidase inhibitor contains the fluorinated polyhydroxyindolizidine compound and a pharmaceutically acceptable salt thereof according to the first or third aspect of the present invention as an active ingredient.

[0025] The fifth aspect of the present invention provides use of the glycosidase inhibitor described in the fourth aspect of the present invention in inhibiting glycosidase.

[0026] The sixth aspect of the present invention provides use of the glycosidase inhibitor described in the fourth aspect of the present invention in the preparation of a drug;

[0027] Preferably, the drug is selected from at least one of the following drugs: drugs for preventing and / or treating diabetes; drugs for preventing and / or treating Gaucher's disease; drugs for preventing and / or treating tumors; antiviral drugs; antibacterial drugs; and drugs for preventing and / or treating Pompe disease.

[0028] Through the above technical scheme, the fluorinated polyhydroxy indolizidine compounds and pharmaceutically acceptable salts thereof prepared by the present invention can be applied to glycosidase inhibitors, have high α-mannosidase inhibitory activity or α-rhamnosidase inhibitory activity, and have high selectivity. At the same time, the introduction of fluorine atoms into the chemical structure of the fluorinated polyhydroxy indolizidine compounds and pharmaceutically acceptable salts thereof can improve their fat solubility, and they can be used in the field of drug preparation. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 This is the single crystal diffraction structure of the compound represented by formula (5-2) in Example 2. DETAILED DESCRIPTION

[0030] The endpoints and any values ​​of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of each range, the endpoint values ​​of each range and the individual point values, and the individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.

[0031] In the present invention, the terms involved are uniformly interpreted as follows:

[0032] R and S represent two opposite absolute configurations known in the field of organic chemistry.

[0033] D and L represent two opposite relative configurations known in the field of organic chemistry.

[0034] The carbon atoms at positions 1, 2, 3, 4, 5, 6, 7, 8 and 8a represent the carbon atoms indicated in the compound represented by formula (1).

[0035]

[0036] "Number (or number + a) + R or S" represents the carbon atom with the corresponding absolute configuration in formula (1), such as: 1S represents the carbon atom at position 1 with an absolute configuration of S in formula (1); 8aR represents the carbon atom at position 8a with an absolute configuration of R in formula (1).

[0037] “D or L-substance name” refers to the substance with the corresponding relative configuration, such as: L-ribose refers to ribose with a relative configuration of L; D-ribose refers to ribose with a relative configuration of D.

[0038] The first aspect of the present invention provides a fluorinated polyhydroxy indolizidine compound and a pharmaceutically acceptable salt thereof, wherein the compound has a chemical structure shown in formula (1):

[0039]

[0040] Among them, R 1 is hydrogen and R 1’ is fluorine, or R 1 is fluorine and R 1’ is hydrogen, or R 1 is fluorine and R 1’ For fluorine;

[0041] Among them, R 2 is hydrogen or acyl;

[0042] Among them, R 3 and R 4 are each independently hydrogen, or R 3 and R 4 The combination of forms a propylidene group;

[0043] Wherein, in Formula 1, the stereo configurations of the carbon atoms at positions 1, 2, 8 and 8a are each independently R or S.

[0044] Preferably, the fluorinated polyhydroxyindolizidine compounds and pharmaceutically acceptable salts thereof do not include the compound represented by formula (1-2):

[0045]

[0046] Preferably, in some embodiments of the present invention, preferably, the stereo configuration of the carbon atoms at positions 1, 2, 8 and 8a is selected from "1R, 2S, 8S, 8aS", "1S, 2R, 8R, 8aR", "1R, 2S, 8R, 8aS" or "1S, 2R, 8S, 8aR".

[0047] More preferably, in some embodiments of the present invention, preferably, the fluorinated polyhydroxy indolizidine compound and a pharmaceutically acceptable salt thereof are selected from one of formula (1-1), formula (1-3) to formula (1-12):

[0048]

[0049]

[0050] The second aspect of the present invention provides a method for synthesizing fluorinated polyhydroxy indolizidine compounds and pharmaceutically acceptable salts thereof, the method comprising:

[0051] (a) subjecting the compound represented by formula (2) to a first oxidation reaction with a first oxidizing agent to obtain an aldehyde product, and then subjecting the product to an addition reaction with an organometallic reagent in the presence of a medium A to obtain a compound represented by formula (3);

[0052]

[0053] Among them, R 5 is a carbonyl group or an acyl group; R 3’ and R 4’ The combination of forms a propylidene group;

[0054] (b) subjecting the compound represented by formula (3) to a protection reaction with a protecting group reagent to obtain a compound represented by formula (4), and then subjecting the compound represented by formula (5) to a second oxidation reaction with a second oxidizing reagent;

[0055]

[0056] Among them, R 2’ is an alkoxymethyl group, an alkylsilyl group or an acyl group;

[0057] (c) in the presence of a catalyst, subjecting the compound represented by formula (5) to a fluorination reaction with a fluorination agent to obtain a compound represented by formula (6), and then subjecting the compound represented by formula (7) to a cyclization reaction with a reagent I in the presence of a medium B;

[0058]

[0059] Among them, R 1 and R 1’ is fluorine or hydrogen, but not both;

[0060] (d) subjecting the compound represented by formula (7) to a deprotection reaction with a hydrogen source reagent, reagent I and reagent II to obtain a compound represented by formula (1) and a pharmaceutically acceptable salt thereof;

[0061]

[0062] Among them, R 1 , R 1’ , R 2 , R 3 and R 4 The definition of is the same as that described in the first aspect of the present invention.

[0063] Wherein, in step (d), when the compound represented by formula (7) reacts chemically with only the hydrogen source reagent and reagent I, a compound represented by formula (8-1) is obtained.

[0064]

[0065] Wherein, in step (d), when the compound represented by formula (7) reacts chemically with reagent II only, a compound represented by formula (8-2) is obtained.

[0066]

[0067] In some embodiments of the present invention, preferably, in step (a), the compound represented by formula (2) is compound 2-1 (Formula 2-1) or compound 2-2 (Formula 2-2),

[0068]

[0069] In some embodiments of the present invention, preferably, in step (a), the first oxidizing agent is selected from Jones reagent, Dess-martin oxidant, swern oxidant, Ley-Griffith oxidant; preferably Dess-martin oxidant, swern oxidant; more preferably Dess-martin oxidant.

[0070] In some embodiments of the present invention, preferably, the molar ratio of the compound represented by formula (2) to the first oxidizing agent is 1:(1.1-50), preferably 1:(1.5-2).

[0071] In some embodiments of the present invention, preferably, the temperature of the first oxidation reaction is -20°C to 10°C, preferably -10°C to 0°C; the reaction time of the first oxidation reaction is 0.3-2h, preferably 0.3-0.5h.

[0072] In some embodiments of the present invention, preferably, the organometallic reagent is selected from 3-butenyl metal bromide reagents; preferably at least one of 3-butenyl magnesium bromide and 3-butenyl zinc bromide; more preferably 3-butenyl magnesium bromide.

[0073] In some embodiments of the present invention, preferably, the medium A is an aprotic solvent; preferably at least one selected from diethyl ether, tetrahydrofuran, dioxane and dichloromethane; more preferably tetrahydrofuran and / or diethyl ether.

[0074] In some embodiments of the present invention, preferably, R 5 It is tert-butyloxycarbonyl, benzyloxycarbonyl, fluorenyloxycarbonyl, acetyl or benzoyl.

[0075] In some embodiments of the present invention, preferably, the molar ratio of the compound represented by formula (2) to the organometallic reagent is 1:(1.2-10), preferably 1:(1.2-3).

[0076] In some embodiments of the present invention, preferably, the amount of the medium A used is 2-200 mL, more preferably 5-50 mL, relative to 1 g of the compound represented by formula (2).

[0077] In some embodiments of the present invention, preferably, the temperature of the addition reaction is -20°C to 10°C, preferably -10°C to 0°C; the reaction time of the addition reaction is 0.3-2h, preferably 0.3-0.5h.

[0078] In some embodiments of the present invention, preferably, in step (b), the molar ratio of the protecting group reagent to the compound represented by formula (3) is (1.2-1):1.

[0079] In some embodiments of the present invention, preferably, the temperature of the protection reaction is -20°C to 10°C, preferably -10°C to 0°C; the reaction time of the protection reaction is 0.3-2h, preferably 0.3-0.5h.

[0080] In some embodiments of the present invention, preferably, R 2 It is methoxymethyl, ethoxymethyl, tert-butyldimethylsilyl or acetyl.

[0081] In some embodiments of the present invention, preferably, the second oxidizing agent is selected from at least one of ozone, osmium tetroxide, alkaline potassium permanganate, and sodium periodate; preferably osmium tetroxide and sodium periodate; in some embodiments of the present invention, preferably, the molar ratio of the second oxidizing agent to the compound represented by formula (4) is (0.2-0.3):1.

[0082] In some embodiments of the present invention, the temperature of the second oxidation reaction is -20°C to 10°C, preferably -10°C to 0°C; the reaction time of the second oxidation reaction is 0.3-2h, preferably 0.3-0.5h.

[0083] In some embodiments of the present invention, preferably, in step (c), the reagent I is selected from at least one of Raney nickel, Pd / C, palladium black, palladium hydroxide, platinum oxide, and platinum black;

[0084] In some embodiments of the present invention, preferably, the reagent I is selected from at least one of Pd / C, palladium black, and palladium hydroxide; more preferably selected from at least one of Pd / C, palladium black, and palladium hydroxide.

[0085] In some embodiments of the present invention, preferably, the mass ratio of the compound represented by formula (6) to the reagent I is 1:(0.1-5), preferably 1:(0.1-0.2).

[0086] In some embodiments of the present invention, preferably, the catalyst is selected from small molecule amine catalysts, preferably at least one of R-Α,Α-bis(3,5-ditrifluoromethylphenyl)prolinol, S-Α,Α-bis(3,5-ditrifluoromethylphenyl)prolinol and DL-proline.

[0087] In some embodiments of the present invention, preferably, the molar ratio of the catalyst to the compound represented by formula (5) is (0.01-0.03):1.

[0088] In some embodiments of the present invention, preferably, the fluorination agent is selected from 1-chloromethyl-4-fluoro-1,4-diazobicyclo[2.2.2]octane bis(tetrafluoroborate) and N-fluorobisbenzenesulfonamide (NFSI); preferably N-fluorobisbenzenesulfonamide (NFSI).

[0089] In some embodiments of the present invention, preferably, the molar ratio of the fluorination agent to the compound represented by formula (5) is (1.2-50):1, preferably (1.2-4):1.

[0090] In some embodiments of the present invention, preferably, the temperature of the fluorination reaction is -20°C to 10°C, preferably -10°C to 0°C; the reaction time of the fluorination reaction is 0.3-2h, preferably 0.3-0.5h.

[0091] In some embodiments of the present invention, preferably, the medium B is selected from at least one of dichloromethane, chloroform, tetrahydrofuran, diethyl ether, ethyl acetate, acetic acid, water, dioxane, methanol, ethanol, acetonitrile, formamide and N,N-dimethylformamide.

[0092] In some embodiments of the present invention, preferably, the reaction temperature of the cyclization reaction is 0-50°C, preferably 10-30°C; the reaction time is 6-100h, preferably 6-12h.

[0093] In some embodiments of the present invention, preferably, in step (d), the reagent I is selected from at least one of Raney nickel, Pd / C, palladium black, palladium hydroxide, platinum oxide, and platinum black.

[0094] In some embodiments of the present invention, preferably, the reagent II is selected from at least one of sodium carbonate, sodium methoxide, potassium carbonate, lithium carbonate, sodium hydroxide, and sodium potassium hydroxide; preferably potassium carbonate or sodium carbonate.

[0095] In some embodiments of the present invention, preferably, the hydrogen source reagent is selected from at least one of hydrogen, sodium borohydride and ammonium formate, preferably hydrogen.

[0096] In some embodiments of the present invention, preferably, the molar ratio of the compound represented by formula (7) to reagent I is 1:(0.1-50), preferably 1:(0.1-0.2).

[0097] In some embodiments of the present invention, preferably, the molar ratio of the compound represented by formula (7) to reagent II is 1:(1.1-10), preferably 1:(1.1-1.2).

[0098] In some embodiments of the present invention, preferably, the temperature of the deprotection reaction is -20°C to 10°C, preferably -10°C to 0°C; the reaction time of the deprotection reaction is 0.3-2h, preferably 0.3-0.5h.

[0099] In the present invention, the salts in the fluorinated polyhydroxyindolizidine compounds and pharmaceutically acceptable salts thereof include but are not limited to inorganic salts such as hydrochlorides, sulfates, nitrates, phosphates, and organic salts such as acetates, fumarates, maleates, oxalates, methanesulfonates, benzenesulfonates, and p-toluenesulfonates.

[0100] The third aspect of the present invention provides a fluorinated polyhydroxyindolizidine compound prepared by the method described in the second aspect of the present invention.

[0101] The fourth aspect of the present invention provides a glycosidase inhibitor, characterized in that the glycosidase inhibitor contains the fluorinated polyhydroxyindolizidine compound and a pharmaceutically acceptable salt thereof according to the first or third aspect of the present invention as an active ingredient.

[0102] The fifth aspect of the present invention provides use of the glycosidase inhibitor described in the fourth aspect of the present invention in inhibiting glycosidase.

[0103] The glycosidase is at least one glycosidase selected from the group consisting of α-glucosidase, β-glucosidase, α-galactosidase, β-galactosidase, α-mannosidase, β-mannosidase, α-L-fucosidase, α,α-trehalase, α-L-rhamnosidase, amyloglucosidase and β-glucuronidase, preferably α-mannosidase and α-L-rhamnosidase, and the glycosidase inhibitor has relatively high inhibitory activity against the above two enzymes and has good selectivity.

[0104] The sixth aspect of the present invention provides the use of the glycosidase inhibitor described in the fourth aspect of the present invention in the preparation of a drug;

[0105] In some embodiments of the present invention, preferably, the drug is selected from at least one of the following drugs: drugs for preventing and / or treating diabetes; drugs for preventing and / or treating Gaucher's disease; drugs for preventing and / or treating tumors; antiviral drugs; antibacterial drugs; drugs for preventing and / or treating Pompe disease.

[0106] Optionally, a pharmaceutically acceptable carrier may be added to the above-mentioned drug, including at least one of conventional diluents, excipients, fillers, binders, wetting agents, disintegrants, absorption promoters, surfactants, adsorption carriers, lubricants and other optional additives in the medical field.

[0107] The drug prepared by using the compound of the structure shown in formula (1) or its pharmaceutically acceptable hydrate or drug complex can be prepared into various forms such as injection, tablet, powder, granule, capsule, oral liquid, ointment, cream, etc. The drugs in the above various dosage forms can be prepared according to conventional methods in the pharmaceutical field.

[0108] The drug can be administered by various routes of administration, including but not limited to oral, inhalation, rectal, transdermal, transmucosal enteral administration, and subcutaneous, intramuscular or intravenous administration. The compound of the structure shown in the present invention or its pharmaceutically acceptable hydrate or drug complex can be administered alone or together with other known diabetes treatment, antiviral, antibacterial, antitumor and lysosomal storage disease drugs.

[0109] The present invention will be described in detail below through examples. In the following examples, the structures of the compounds are characterized by 300MHz, 400MH or 500MHz liquid NMR, and the structures of the compounds are mainly determined by NMR hydrogen spectrum and carbon spectrum, and high-resolution mass spectrometry is used to assist in identification. The commercially available L-ribose of J&K Company, product number: 302658 | CAS: 24259-59-4 or D-ribose product number: 515642 | CAS: 50-69-1 is used as the starting material for preparation, and L-ribose is used as the starting material for the preparation example.

[0110] Preparation Example

[0111] This embodiment is used to illustrate the preparation method of raw materials 2-1 and 2-2 in the following examples.

[0112]

[0113] Commercially available L-ribose (compound represented by GFT-1) is used as the starting material, and the hydroxyl groups at positions 2, 3 and 4 are protected by propylidene groups (compound represented by GFT-2) and silicon groups (compound represented by GFT-3), respectively. Hydroxylamine hydrochloride is used to open the hemiacetal (compound represented by GFT-4), and then a leaving group (compound represented by GFT-5) is made. Subsequently, the silicon group is removed under the action of tetrabutylammonium fluoride (TBAF) (compound represented by GFT-6), and a ring-closing reaction is completed (compound represented by GFT-7). Finally, benzyl chloroformate is used to protect the exposed amino group to obtain the compound represented by 2-1. Compound 2-2 is its enantiomer, which can be prepared from commercial D-ribose as the starting material. The process is exactly the same and will not be repeated here.

[0114] Formula (2-1) [α] D 26 –33.6 (c 2.0, CH2Cl2); ν max / cm -1 3428w, 2987m, 2940m, 1670s, 1419s, 1346m, 1216m, 1213m, 1085s; 1H NMR (500MHz, CDCl3) δ7.38–7.30(m,5H),5.13(ABq,J=12.4Hz,2H),4.85–4.78(m,1H),4.76–4. 67(m,1H),4.51–4.32(m,1H),4.02–3.78(m,3H),3.70–3.48(m,2H),1.49(s,3H),1.33(s,3H); 13 C NMR (75MHz, CDCl3) δ156.4,136.2,128.6,128.2,128.1,112.4,80.4,77.6,67.5,63.6,62.1,52.0,26.4,24.8; HRMS (ESI): m / z calcdfor C 16 H 22 NO5 + [M+H] + 308.14925; found 308.14921.

[0115] Example 1

[0116] This example is used to illustrate the C6-fluoroswainsonine derivative and its preparation method of the present invention.

[0117]

[0118] Compound (2-1) (6.14 g, 20 mmol) was dissolved in 250 mL of dry dichloromethane, and Dess-Martin oxidant (first oxidizing agent, 8.48 g, 20 mmol) was added to the reaction. The first oxidation reaction was carried out at 25°C for 30 min. The reaction was monitored by TLC plate. 20 mL of saturated sodium thiosulfate solution was added to quench the reaction, and the reaction was washed with 20 mL of saturated sodium bicarbonate solution. Finally, the aqueous phase was extracted with dichloromethane for 3 times, and the organic phases were combined, washed with saturated sodium chloride solution, and dried with anhydrous MgSO4, filtered, and the solvent was removed by distillation under reduced pressure to obtain 6.08 g of product aldehyde. It can be directly used for the next step without purification.

[0119] The crude product aldehyde was dissolved in 250 mL of dry tetrahydrofuran (medium A), and 3-butenylmagnesium bromide solution (organometallic reagent, 30 mmol) was slowly injected into it at 0°C under Ar protection, with obvious exothermic phenomenon. After the addition was completed, the addition reaction was carried out at this temperature for 30 min, and saturated ammonium chloride solution was added to quench the addition reaction. The aqueous phase was extracted 3 times with ethyl acetate, and the organic phases were combined, washed with saturated sodium chloride solution, and dried with anhydrous MgSO4, filtered, and distilled under reduced pressure to remove the solvent to obtain the addition product formula (3-1) (5.78 g, 16 mmol), of which the diastereomer 3-2 was separated to 650 mg, and the two-step yield of compound (3-1) was 80%.

[0120] The compound (3-1) was dissolved in 200 mL of dichloromethane, and acetic anhydride (protective agent reagent, 1.96 g, 19.2 mmol) and triethylamine (3.23 g, 32 mol) were added. The mixture was heated to 50°C and the protection reaction was carried out for 4 hours. After the reaction was completed, saturated aqueous sodium bicarbonate solution was added to neutralize it. The aqueous phase was extracted with ethyl acetate for 3 times, the organic phases were combined, anhydrous MgSO4 was added to dry, filtered, and the solvent was removed to obtain 6.45 g of the product formula (4-1).

[0121] The above crude product 4-1 was dissolved in 100 mL of acetone, and 2 mL of 10% aqueous osmium tetroxide solution and 25 mL of 30% aqueous N-methylmorpholine N-oxide (NMO) (second oxidizing agent) oxide solution were added, and stirred at room temperature overnight. 5 mL of saturated sodium thiosulfate was added, and the aqueous phase was extracted 3 times with ethyl acetate. The organic phases were combined, and anhydrous MgSO4 was added to dry. The mixture was filtered and the solvent was removed to obtain a yellow syrup. The syrup was dissolved in 30 mL of methanol, and sodium periodate (third oxidizing agent) was added to carry out a second oxidation reaction at room temperature for 1 hour. The white insoluble matter in the reaction system was filtered out, the solvent was dried, and water was added to dissolve the mixture. The aqueous phase was extracted 3 times with ethyl acetate. The organic phases were combined, and anhydrous MgSO4 was added to dry. The mixture was filtered and the solvent was removed to obtain 5.21 g of a crude product.

[0122] The crude product aldehyde obtained in the above reaction was dissolved in 120 mL of methyl tert-butyl ether, and S-Α,Α-bis(3,5-ditrifluoromethylphenyl)prolinol (S-configuration chiral amine catalyst) was added. After stirring for ten minutes, the fluorination reagent NFSI (10.01 g, 32 mmol) was added, and the fluorination reaction was carried out at room temperature overnight. The insoluble matter was filtered off and dissolved in methanol (medium B). A catalytic amount of palladium carbon was directly added, and the cyclization reaction was carried out under a hydrogen atmosphere overnight to obtain compound formula (5-1) (3.10 g, 11.36 mmol), with a three-step yield of 71%.

[0123] The compound represented by formula (5-1) (200 mg) was dissolved in 10 mL of methanol, and 1 mL of 1N HCl solution and 10 mg of Pd / C (reagent I) were added. The mixture was stirred overnight under H2 conditions (hydrogen source reagent), and then Pd / C was filtered off. The solvent was spin-dried, and potassium carbonate (reagent II) was added to the resulting hydrochloride solution in 10 mL of methanol. The deprotection reaction was carried out for 2 h, and the mixture was spin-dried to obtain the hydrochloride of formula (1-1) (137 mg, 0.72 mmol) with a yield of 98%.

[0124] Formula (1-1): [α] D 26 -94.6 (c 0.5, CH3OH); ν max / cm -1 3366w, 2949m, 2815m, 1650m, 1403m, 1194m, 1013m, 992w;

[0125] 1 H NMR(500MHz,D2O)δ4.66(dm,J=47.6Hz,1H,H6),4.42-4.36(m,1H,H2),4.28-4.21(m,1H,H1),3.87(t,J=9.9Hz,1H,H8 ),3.31-3.24(m,1H,H5),2.88(d,J=10.7Hz,1H,H3),2.71-2.66(m,1H,H7),2.59-2.52(m,1H,H5),2.17-2.04(m,2H,H3 and H8a),1.56-1.46(m,1H,H7);

[0126] 13 C NMR(125MHz,D2O)δ86.3(d,J=168.5Hz,C6),70.9(8a),68.8(C2),68.2(C1),62 .6(d,J=13.2Hz,C8),58.9(C3),54.2(d,J=26.7Hz,C5),38.4(d,J=17.7Hz,C7);

[0127] 19 F NMR (376MHz, CDCl3) δ-183.1;

[0128] HRMS(ESI):m / z calcd for C8H 15 NFO3 + [M+H] + 192.10305, found 192.10298.

[0129] Embodiment 2:

[0130] This embodiment is used to illustrate the C6-fluoroswainsonine derivative and its preparation method of the present invention.

[0131]

[0132] The method described in Example 1 is different in that R-Α,Α-bis(3,5-ditrifluoromethylphenyl)prolinol (R-configured chiral amine catalyst) is used instead of S-Α,Α-bis(3,5-ditrifluoromethylphenyl)prolinol (S-configured chiral amine catalyst), and the compound represented by formula (1-2) is obtained by cation exchange resin.

[0133] Formula (1-2): [α] D 26 –63.1(c 1.7,CH3OH); ν max / cm -1 3374s, 2952m, 2816m, 1647w, 1635w, 1435m, 1339m, 1136s, 1097s, 1063m, 943m;

[0134] 1 H NMR (400MHz, D2O) δ5.02 (dm, J=46.0Hz, 1H, H6), 4.44–4.40 (m, 1H, H2), 4.32 (dd, J=5.5, 3. 8Hz,1H,H1),4.18–4.11(m,1H,H8),3.26(t,J=13.0Hz,1H,H5),2.96(dd,J=10.8,2.4Hz,1 H,H3),2.63(dd,J=10.7,8.0Hz,1H,H3),2.52–2.43(m,1H,H7),2.28(dd,J=43.7,13.1Hz, 1H, H5), 2.08 (dd, J=9.6, 3.6Hz, 1H, H8a), 1.57 (dddd, J=47.3, 14.2, 11.4, 2.7Hz, 1H, H7);

[0135] 13 C NMR(100MHz,D2O)δ89.0(d,J=166.6Hz,C6),71.6(C8a),69.4(C2),68.8(C1),62.5(C8),60.1(C3),54.6(d,J=18.5Hz,C5),36.7(d,J=20.8Hz,C7);

[0136] 19 F NMR (376MHz, CDCl3) δ–178.1;

[0137] HRMS(ESI):m / z calcd.for C8H 15 NFO3 + [M+H] + 192.10305; found 192.10320.

[0138] Depend on Figure 1 It can be seen that the route of Example 2 can successfully synthesize the compound represented by formula (5-2). It is a common operation in the art to remove the protecting group according to this route to obtain the compound represented by formula (1-2). 1 H NMR, 13 CNMR, 19 Compounds 1-2 can be characterized by F NMR and HRMS (ESI). The starting materials of Examples 1 and 3-12 have the same molecular formula as that of Example 2, and the only difference is the different configuration of individual carbon atoms. Since the functional groups and reaction conditions for the cyclization reaction in each example are conventional operations well known to those skilled in the art and are exactly the same, Figure 1 It can be inferred that the compound represented by the above formula (5-1), the compound represented by the following formula (5-3) to the compound represented by the following formula (5-6), and the compound represented by the following formula (8-1) to the compound represented by the following formula (8-6) can all be successfully synthesized. 1 H NMR, 13 C NMR, 19 The final products were characterized by F NMR and HRMS (ESI).

[0139] Example 3

[0140] This embodiment is used to illustrate the C6-fluoroswainsonine derivative and its preparation method of the present invention.

[0141]

[0142] The method described in Example 1 is used, except that DL-proline is used instead of S-Α,Α-bis(3,5-ditrifluoromethylphenyl)prolinol (S-configuration chiral amine catalyst) to obtain a compound represented by formula (1-3).

[0143] Formula (1-3): [α] D 26 –70.9 (c 0.75, CH3OH); ν max / cm -1 3354s,2949w,2822m,1389m,1312m,1268w,1167m,1117m,1054m,972w,948m;

[0144] 1H NMR(400MHz,D2O)δ4.47–4.40(m,1H,H2),4.30–4.27(m,1H,H1),4.02(td,J=10. 3,9.8,5.1Hz,1H,H8),3.24(t,J=11.4Hz,1H,H5),2.95(dd,J=10.8,2.3Hz,1H,H3 ),2.72–2.67(m,1H,H3),2.66–2.55(m,1H,H7),2.47(ddd,J=29.1,11.9,2.8Hz,1 H, H5), 2.20 (dd, J=9.6, 3.6Hz, 1H, H8a), 1.86 (dtd, J=34.8, 12.3, 6.7Hz, 1H, H7);

[0145] 13 C NMR(100MHz,D2O)δ120.9(t,J=239.9Hz,C6),70.8(C8a),69.1(C2),68.6(C1),62.7(d, J=12.8Hz, C8), 59.1 (C3), 56.0 (dd, J=31.5, 23.7Hz, C5), 40.0 (dd, J=24.2, 20.9Hz, C7);

[0146] 19 F NMR (376MHz, CDCl3) δ –94.2 (d, J = 248.2Hz), –96.1 (d, J = 247.3Hz);

[0147] HRMS(ESI):m / z calcd for C8H 14 NF2O3 + [M+H] + 210.09363,found210.09408.

[0148] Example 4

[0149] This example is used to illustrate the C6-fluoroswainsonine derivative and its preparation method of the present invention.

[0150]

[0151] According to the method of Example 1, the compound represented by formula (1-4) was prepared.

[0152] Formula (1-4): [α] D 29 –53.7(c 1.5,CH3OH); νmax / cm -13375s,2951m,2807w,1633w,1471w,1444s,1086m,1037s,1003s,977m,870m,831m;

[0153] 1 H NMR(500MHz,D2O)δ5.00(dm,J=47.9Hz,1H,H6),4.46(s,1H,H8),4.40–4.37(m,1H,H1),4.35–4.32(m,1H,H2),3.43–3.35(m,1H,H5),2.93(d,J =11.0Hz,1H,H3),2.62(dd,J=10.7,7.4Hz,1H,H3),2.35–2.32(m,1H,H7 ),2.29–2.28(m,1H,H8a),2.22–2.16(m,1H,H5),1.69–1.61(m,1H,H7);

[0154] 13 C NMR(125MHz,D2O)δ86.4(d,J=165.4Hz,C6),71.5(C1),69.3(C2),66.0(C8a),65 .9(d,J=14.7Hz,C8),59.5(C3),55.6(d,J=26.3Hz,C5),36.6(d,J=18.4Hz,C7);

[0155] 19 F NMR (376MHz, CDCl3) δ–189.6;

[0156] HRMS(ESI):m / z calcd.for C8H 15 NFO3 + [M+H] + 192.10305; found 192.10269.

[0157] Example 5

[0158] This example is used to illustrate the C6-fluoroswainsonine derivative and its preparation method of the present invention.

[0159]

[0160] According to the method of Example 2, the compound represented by formula (1-5) was prepared.

[0161] Formula (1-5): νmax / cm -1 3378s,1634w,1407m,1358m,1136s,1098m,1003w,914m,784m;

[0162] 1 H NMR(500MHz,D2O)δ4.87(dm,J=46.2Hz,1H,H6),4.42–4.38(m,2H,H1 and H8),4.31–4.28(m,1H,H2),3.37(t,J=13.7Hz,1H,H5),2.98(d,J=10.8Hz,1H,H3 ),2.50–2.47(m,1H,H3),2.34(dd,J=42.6,13.2Hz,1H,H5),2.25–2.19(m,2H,H7 and H8a),1.79(dd,J=47.5,16.1Hz,1H,H7);

[0163] 13 C NMR(125MHz,D2O)δ87.8(d,J=168.6Hz,C6),72.4(C1),68.7(C2),66.0(C8),65.4(C8a),59.8(C3),55.9(d,J=19.4Hz,C5),34.4(d,J=18.9Hz,C7);

[0164] 19 F NMR (376MHz, CDCl3) δ–174.3;

[0165] (ESI):m / z calcd for C8H 15 FNO3 + [M+H] + 192.10305, found 192.10284.

[0166] Example 6

[0167] This example is used to illustrate the C6-fluoroswainsonine derivative and its preparation method of the present invention.

[0168]

[0169] According to the method described in Example 3, the compound represented by formula (1-6) was prepared.

[0170] Formula (1-6): νmax / cm -1 3388vs,2929w,2820w,1653w,1429w,1362w,1279m,1154s,1114s,1079s,1025m,928s,876w;

[0171] 1H NMR(400MHz,D2O)δ4.50(brs,1H,H8),4.46(t,J=5.5Hz,1H,H1),4.38–4.35(m,1H,H5),3.37(t,J=12.2Hz,1H,H5),3.02(d,J=9.6Hz,1H,H3),2. 63(dd,J=10.8,7.1Hz,1H,H3),2.51(ddd,J=30.6,11.9,2.5Hz,1H,H5), 2.40(d,J=4.5Hz,1H,H8a),2.38–2.30(m,1H,H7),2.17–2.02(m,1H,H7);

[0172] 13 C NMR(100MHz,D2O)δ120.7(dd,J=243.8,236.5Hz,C6),71.7(C1),69.4(C2),65.6(C8a),6 4.6(d,J=12.8Hz,C8),59.1(C3),57.3(dd,J=31.8,24.5Hz,C5),38.1(t,J=22.1Hz,C7);

[0173] 19 F NMR(376MHz,D2O)δ–91.4(d,J=246.2Hz,1F),–95.4(d,J=246.2Hz,1F);

[0174] HRMS(ESI+):m / z calcd.for C8H 14 NF2O3 + [M+H] + 210.09363; found 210.09338.

[0175] Example 7

[0176] This example is used to illustrate the C6-fluoroswainsonine derivative and its preparation method of the present invention.

[0177]

[0178] According to the method described in Example 1, the compound represented by formula (1-7) was prepared.

[0179] Formula (1-7): ν max / cm -1 3375s, 2953m, 2817m, 1647w, 1635w, 1436m, 1339m, 1137s, 1098s, 1063m, 943m;

[0180] 1 H NMR(400MHz,D2O)δ5.02(dm,J=46.0Hz,1H,H6),4.44–4.40(m,1H,H2),4.32(dd,J=5.5,3. 8Hz,1H,H1),4.18–4.11(m,1H,H8),3.26(t,J=13.0Hz,1H,H5),2.96(dd,J=10.8,2.4Hz,1 H,H3),2.63(dd,J=10.7,8.0Hz,1H,H3),2.52–2.43(m,1H,H7),2.28(dd,J=43.7,13.1Hz, 1H, H5), 2.08 (dd, J=9.6, 3.6Hz, 1H, H8a), 1.57 (dddd, J=47.3, 14.2, 11.4, 2.7Hz, 1H, H7);

[0181] 13 C NMR(100MHz,D2O)δ89.0(d,J=166.4Hz,C6),71.6(C8a),69.4(C2),68.8(C1),62.5(C8),60.0(C3),54.6(d,J=18.5Hz,C5),36.7(d,J=20.8Hz,C7);

[0182] 19 F NMR (376MHz, CDCl3) δ–180.5;

[0183] HRMS(ESI):m / z calcd.for C 11 H 19 NFO3 + [M+H] + 192.10305; found 192.10269.

[0184] Example 8

[0185] This example is used to illustrate the C6-fluoroswainsonine derivative and its preparation method of the present invention.

[0186]

[0187] According to the method described in Example 2, the compound represented by formula (1-8) was prepared.

[0188] Formula (1-8): νmax / cm -1 3368w, 2950m, 2816m, 1652w, 1404s, 1194m, 1013m, 992m;

[0189] 1H NMR(400MHz,D2O)δ4.79(dm,J=48.4Hz,1H,H6),4.96–4.45(m,1H,H2),4.32–4.30(m,1H,H3),4.00–3.94(m,1H,H8 ),3.40–3.36(m,1H,H5),3.02–3.00(m,1H,H1),2.95–2.90(m,1H,H1),2.61–2.56(m,1H,H7),2.45–2.36(m,2H,H4 and H5),1.69–1.57(m,1H,H7);

[0190] 13 C NMR(100MHz,D2O)δ86.2(d,J=170.0Hz,C6),70.9(C4),69.0(C2),68.5(C3),62 .4(d,J=14.0Hz,C8),59.0(C1),54.2(d,J=27.0Hz,C5),37.9(d,J=18.0Hz,C7);

[0191] 19 F NMR(376MHz, CDCl3)δ–183.0;

[0192] HRMS(ESI):m / z calcd for C8H 15 NFO3 + [M+H] + 192.10305, found 192.10271.

[0193] Example 9

[0194] This example is used to illustrate the C6-fluoroswainsonine derivative and its preparation method of the present invention.

[0195]

[0196] According to the method described in Example 3, the compound represented by formula (1-9) was prepared.

[0197] Formula (1-9): νmax / cm -1 3473w, 2986m, 2939m, 2814m, 1733s, 1457w, 1356w, 1241vs, 1177m, 1157m, 1119s, 1079m, 1039s, 978w, 950m, 863m;

[0198] [α] D 26 +81.2 (c 0.75, CH3OH); ν max / cm-1 3354s,2949w,2822m,1389m,1312m,1268w,1167m,1117m,1054m,972w,948m;

[0199] 1 H NMR(400MHz,D2O)δ4.46–4.40(m,1H,H2),4.30–4.26(m,1H,H1),4.02(td,J=10. 3,9.8,5.1Hz,1H,H8),3.24(t,J=11.4Hz,1H,H5),2.94(dd,J=10.8,2.3Hz,1H,H3 ),2.72–2.67(m,1H,H3),2.65–2.55(m,1H,H7),2.47(ddd,J=29.1,11.9,2.8Hz,1 H, H5), 2.20 (dd, J=9.6, 3.6Hz, 1H, H8a), 1.86 (dtd, J=34.8, 12.3, 6.7Hz, 1H, H7);

[0200] 13 C NMR(100MHz,D2O)δ120.9(t,J=239.8Hz,C6),70.8(C8a),69.1(C2),68.6(C1),62.7(d, J=12.7Hz, C8), 59.1 (C3), 56.0 (dd, J=31.5, 23.7Hz, C5), 40.0 (dd, J=24.2, 20.9Hz, C7);

[0201] 19 F NMR (376MHz, CDCl3) δ –94.2 (d, J = 247.6Hz, 1F), – 96.1 (d, J = 246.8Hz, 1F);

[0202] HRMS(ESI):m / z calcd for C8H 14 NF2O3 + [M+H] + 210.09363,found210.09360.

[0203] Example 10

[0204] This example is used to illustrate the C6-fluoroswainsonine derivative and its preparation method of the present invention.

[0205]

[0206] According to the method described in Example 1, the compound represented by formula (1-10) was prepared.

[0207] Formula (1-10): ν max / cm -1 3378s, 1634w, 1407m, 1358m, 1136s, 1098m, 1003w, 914m, 784m; νmax / cm -1 3378s,1634w,1407m,1358m,1136s,1098m,1003w,914m,784m;

[0208] 1 H NMR(500MHz,D2O)δ4.91(dm,J=46.6Hz,1H,H6),4.44–4.40(m,2H,H1 and H8),4.31(t,J=6.5Hz,1H,H2),3.39(t,J=14.0Hz,1H,H5),2.99(d,J=11.0Hz,1H,H3),2 .51(dd,J=10.7,7.1Hz,1H,H3),2.34(dd,J=42.7,13.2Hz,1H,H5),2.26–2.20(m,2H,H7 andH8a),1.81(dd,J=47.6,16.2Hz,1H,H7);

[0209] 13 C NMR(125MHz,D2O)δ87.8(d,J=168.3Hz,C6),72.4(C1),68.7(C2),66.0(C8),65.4(C8a),59.8(C3),55.9(d,J=19.7Hz,C5),34.4(d,J=18.2Hz,C7);

[0210] 19 F NMR (376MHz, CDCl3) δ–174.4;

[0211] HRMS(ESI):m / z calcd for C8H 14 FNO3Na + [M+Na] + 214.08499, found 214.08467.

[0212] Embodiment 11

[0213] This example is used to illustrate the C6-fluoroswainsonine derivative and its preparation method of the present invention.

[0214]

[0215] According to the method described in Example 2, the compound represented by formula (1-11) was prepared.

[0216] Formula (1-11): ν max / cm -1 3373s, 2949m, 2805w, 1633w, 1470w, 1442s, 1084m, 1037s, 1003s, 977m, 868m, 831m;

[0217] 1 H NMR (300MHz, CD3OD) δ5.10–4.85(m,1H),4.42–4.36(m,1H),4.32(t,J=5.7Hz,1H),4.25–4.21(m,1H),3.39–3.33(m, 1H),2.98(d,J=10.3Hz,1H),2.47(dd,J=10.4,6.5Hz,1H),2.34–2.29(m,1H),2.11–2.02(m,2H),1.62–1.49(m,1H);

[0218] 13 C NMR (75MHz, CD3OD) δ86.6, 84.3, 72.0, 68.2 (d, J = 169.5Hz),, 66.1 (d, J = 14.3Hz), 60.5, 56.4 (d, J = 26.3Hz), 37.6 (d, J = 18.0Hz);

[0219] HRMS(ESI):m / z calcd.for C8H 15 NFO3 + [M+H] + 192.10305; found 192.10333.

[0220] Example 12

[0221] This example is used to illustrate the C6-fluoroswainsonine derivative and its preparation method of the present invention.

[0222]

[0223] According to the method described in Example 3, the compound represented by formula (1-12) was prepared.

[0224] Formula (1-12): νmax / cm-1 3388vs,2929w,2820w,1653w,1429w,1362w,1279m,1154s,1114s,1079s,1025m,928s,876w;

[0225] 1H NMR(500MHz,D2O)δ4.48(brs,1H,H8),4.46–4.41(m,1H,H1),4.37–4.32(m,1H,H5),3.35(t,J=11.9Hz,1H,H5),3.00(d,J=10.8Hz,1H, H3),2.61(t,J=8.4Hz,1H,H3),2.49(dd,J=30.8,11.8Hz,1H,H5),2.39(s,1H,H8a),2.32(t,J=13.8Hz,1H,H7),2.14–1.99(m,1H,H7);

[0226] 13 C NMR(125MHz,D2O)δ121.1(dd,J=244.5,236.4Hz,C6),72.2(C1),69.9(C2),66.2(C8a),6 5.1(d,J=13.0Hz,C8),59.6(C3),57.9(dd,J=31.8,24.5Hz,C5),38.6(t,J=22.0Hz,C7);

[0227] 19 F NMR(376MHz,D2O)δ–92.0(d,J=246.9Hz,1F),–96.1(d,J=243.9Hz,1F);

[0228] HRMS(ESI):m / z calcd.for C8H 14 NF2O3 + [M+H] + 210.09363; found 210.09368.

[0229] Test Example 1

[0230] This test example is used to illustrate the glycosidase inhibitory activity of the C6-fluoroswainsonine derivatives of the present invention.

[0231] (1) Test materials and sources

[0232] Test compound: C6-fluoroswainsonine derivatives represented by formula (1-1) to formula (1-12) provided by the present invention.

[0233] Experimental Materials: All 4-nitrophenolpyranoside substrates, disaccharides and glycosidases (including α-glucosidase, β-glucosidase, α-glucosidase, β-lactogalactosidase, α-lactomannosidase, β-lactomannosidase, α-lactosylfucosidase, α-trehalase, α-alcosylase rhamnosidase, amyloglucosidase and β-glucuronidase) were purchased from Sigma-Aldrich.

[0234] (2) Test methods

[0235] Kinetic studies were conducted in 50 mM sodium citrate / phosphate buffer at 37°C. Depending on the substrate, the enzyme concentration was 0.1-0.5 mg / mL. Activity tests were performed using 4-nitrophenolpyranoside as the substrate at the optimal activity pH for each enzyme. The substrate, enzyme solution and inhibitor (polyhydroxypyrrolidine compound of the present invention) were incubated at 37°C for 30 minutes, and then the reaction was started in a UV-visible spectrophotometer to measure its absorption of 400 nm wavelength light. Finally, the GraFit program was used for data analysis [see Leatherbarrow, RJ Grafit 4.0; Erithacus Software: Staines, UK, 1998.].

[0236] (3) Evaluation results

[0237] The results of the inhibitory activity of the C6-fluoroswainsonine derivatives provided by the present invention on glycosidase are shown in Tables 1 and 2.

[0238] In Table 1 and Table 2, the percentage is the inhibition rate of the corresponding compound on the enzyme, indicating its IC 50 (μM) values ​​greater than 1000 indicate low inhibitory activity; non-percentage values ​​are the IC values ​​of the corresponding compounds on the enzyme 50 (μM) value, the smaller the value, the higher the inhibitory activity.

[0239] Table 1

[0240]

[0241]

[0242] Table 2

[0243]

[0244]

[0245] It can be seen from the data in the above table that after the C6 position of the left-handed swainsonine is fluorinated in the present invention, it has a higher inhibitory activity against α-mannosidase. The inhibitory activities of our fluorinated compounds 1-2 and 1-3 against mannosidase are increased by 1.46 and 1.7 times, respectively. After the C6 position of the right-handed swainsonine is fluorinated, it has a higher inhibitory activity against α-L-rhamnosidase, and both are highly selective.

[0246] As shown in Table 3, by introducing hydrophobic fluorine atoms into their skeletons, the lipid solubility of compounds 1-1 to 1-12 was increased by about 7-13 times compared with swainsonine (ClogP increased by 0.85-1.11), which can improve the pharmacokinetic properties of the compounds, increase the bioavailability of the compounds, and further reduce side effects.

[0247] Table 3

[0248]

[0249] The preferred embodiments of the present invention are described in detail above, but the present invention is not limited thereto. Within the technical concept of the present invention, the technical solution of the present invention can be subjected to a variety of simple modifications, including the combination of various technical features in any other suitable manner, and these simple modifications and combinations should also be regarded as the contents disclosed by the present invention and belong to the protection scope of the present invention.

Claims

1. A fluorinated polyhydroxy indolizidine compound and a pharmaceutically acceptable salt thereof, characterized in that: The compound has a chemical structure shown in formula (1): Among them, R 1 is hydrogen and R 1’ is fluorine, or R 1 is fluorine and R 1’ is hydrogen, or R 1 is fluorine and R 1’ For fluorine; Among them, R 2 is hydrogen or acyl; wherein R 3 and R 4 each independently is hydrogen; Wherein, in Formula 1, the stereo configurations of the carbon atoms at positions 1, 2, 8 and 8a are each independently R or S.

2. The compound according to claim 1 and its pharmaceutically acceptable salt, characterized in that: The fluorinated polyhydroxy indolizidine compounds do not include the compounds represented by formula (1-2): Preferably, the stereo configuration of the carbon atoms at positions 1, 2, 8 and 8a is selected from "1R, 2S, 8S, 8aS", "1S, 2R, 8R, 8aR", "1R, 2S, 8R, 8aS" or "1S, 2R, 8S, 8aR"; More preferably, the fluorinated polyhydroxy indolizidine compound is selected from one of formula (1-1), formula (1-3) to formula (1-12):

3. A method for synthesizing a fluorinated polyhydroxy indolizidine compound and a pharmaceutically acceptable salt thereof, the method comprising: (a) subjecting the compound represented by formula (2) to a first oxidation reaction with a first oxidizing agent to obtain an aldehyde product, and then subjecting the product to an addition reaction with an organometallic reagent in the presence of a medium A to obtain a compound represented by formula (3); Among them, R 5 is an alkoxycarbonyl group, a benzyloxycarbonyl group, an alkylacyl group, or an arylacyl group; R 3’ and R 4’ The combination of forms a propylidene group; (b) subjecting the compound represented by formula (3) to a protection reaction with a protecting group reagent to obtain a compound represented by formula (4), and then subjecting the compound represented by formula (5) to a second oxidation reaction with a second oxidizing reagent; Among them, R 2’ is an alkoxymethyl group or an acyl group; (c) in the presence of a catalyst, subjecting the compound represented by formula (5) to a fluorination reaction with a fluorination agent to obtain a compound represented by formula (6), and then subjecting the compound represented by formula (7) to a cyclization reaction with a reagent I in the presence of a medium B; (d) subjecting the compound represented by formula (7) to a deprotection reaction with a hydrogen source reagent, reagent I and reagent II to obtain a compound represented by formula (1) and a pharmaceutically acceptable salt thereof; Among them, R 1 , R 1’ , R 2 , R 3 and R 4 The definition is the same as that in claim 1.

4. The method according to claim 3, wherein: In step (a), the first oxidizing agent is selected from Jones reagent, Dess-martin oxidant, Swern oxidant or Ley-Griffith oxidant; preferably Dess-martin oxidant or swern oxidant; more preferably Dess-martin oxidant; and / or, the molar ratio of the compound represented by formula (2) to the first oxidizing agent is 1:(1.1-50), preferably 1:(1.5-2); and / or, the temperature of the first oxidation reaction is -20°C to 10°C, preferably -10°C to 0°C; the reaction time of the first oxidation reaction is 0.3-2h, preferably 0.3-0.5h; And / or, the organometallic reagent is selected from 3-butenyl metal bromide reagent; preferably at least one of 3-butenyl magnesium bromide and 3-butenyl zinc bromide; more preferably 3-butenyl magnesium bromide; And / or, the medium A is an aprotic solvent; preferably at least one selected from diethyl ether, tetrahydrofuran, dioxane and dichloromethane; more preferably tetrahydrofuran and / or diethyl ether; Preferably, R 5 is tert-butyloxycarbonyl, benzyloxycarbonyl, fluorenyloxycarbonyl or acetyl, benzoyl; and / or, the molar ratio of the compound represented by formula (2) to the organometallic reagent is 1:(1.2-10), preferably 1:(1.2-3); and / or, relative to 1 g of the compound represented by formula (2), the amount of the medium A is 2-200 mL, more preferably 5-50 mL; And / or, the temperature of the addition reaction is -20°C to 10°C, preferably -10°C to 0°C; the reaction time of the addition reaction is 0.3-2h, preferably 0.3-0.5h; And / or, in step (b), the molar ratio of the protecting group reagent to the compound represented by formula (3) is (1.2-1):1; And / or, the temperature of the protection reaction is -20°C to 10°C, preferably -10°C to 0°C; the reaction time of the protection reaction is 0.3-2h, preferably 0.3-0.5h; Preferably, R 2’ Methoxymethyl, ethoxymethyl, tert-butyldimethylsilyl or acetyl, benzoyl; And / or, the second oxidizing agent is selected from at least one of ozone, osmium tetroxide, alkaline potassium permanganate, and sodium periodate; preferably osmium tetroxide and sodium periodate; And / or, the molar ratio of the second oxidizing agent to the compound represented by the formula (4) is (0.2-0.3):1; And / or, the temperature of the second oxidation reaction is -20°C to 10°C, preferably -10°C to 0°C; the reaction time of the second oxidation reaction is 0.3-2h, preferably 0.3-0.5h.

5. The method according to claim 3 or 4, wherein: In step (c), the reagent I is selected from at least one of Raney nickel, Pd / C, palladium black, palladium hydroxide, platinum oxide, and platinum black; Preferably, the reagent I is selected from at least one of Pd / C, palladium black, and palladium hydroxide; Preferably, the mass ratio of the compound represented by formula (6) to the reagent I is 1:(0.1-5), preferably 1:(0.1-0.2); And / or, the catalyst is selected from small molecule amine catalysts, preferably at least one of R-Α,Α-bis(3,5-ditrifluoromethylphenyl)prolinol, S-Α,Α-bis(3,5-ditrifluoromethylphenyl)prolinol and DL-proline; Preferably, the molar ratio of the catalyst to the compound represented by formula (5) is (0.01-0.03):1; And / or, the fluorination agent is selected from 1-chloromethyl-4-fluoro-1,4-diazobicyclo[2.2.2]octane bis(tetrafluoroborate), N-fluorobisbenzenesulfonamide; preferably N-fluorobisbenzenesulfonamide; and / or, the molar ratio of the fluorination agent to the compound represented by formula (5) is (1.2-50):1, preferably (1.2-4):1; and / or, the temperature of the fluorination reaction is -20°C to 10°C, preferably -10°C to 0°C; the reaction time of the fluorination reaction is 0.3-2h, preferably 0.3-0.5h; and / or, the medium B is selected from at least one of dichloromethane, chloroform, tetrahydrofuran, ether, ethyl acetate, acetic acid, water, dioxane, methanol, ethanol, acetonitrile, formamide and N,N-dimethylformamide; And / or, the reaction temperature of the cyclization reaction is 0-50°C, preferably 10-30°C; the reaction time is 6-100h, preferably 6-12h.

6. The method according to any one of claims 3 to 5, wherein: In step (d), the reagent I is selected from at least one of Raney nickel, Pd / C, palladium black, palladium hydroxide, platinum oxide, and platinum black; And / or, the reagent II is selected from at least one of sodium carbonate, sodium methoxide, potassium carbonate, lithium carbonate, sodium hydroxide, and sodium potassium hydroxide; preferably potassium carbonate or sodium carbonate; and / or, the hydrogen source reagent is selected from at least one of hydrogen, sodium borohydride and ammonium formate, preferably hydrogen; and / or, the molar ratio of the compound represented by formula (7) to reagent I is 1:(0.1-50), preferably 1:(0.1-0.2); and / or, the molar ratio of the compound represented by formula (7) to reagent II is 1:(1.1-10), preferably 1:(1.1-1.2); And / or, the temperature of the deprotection reaction is -20°C to 10°C, preferably -10°C to 0°C; the reaction time of the deprotection reaction is 0.3-2h, preferably 0.3-0.5h.

7. Fluorinated polyhydroxyindolizidine compounds and pharmaceutically acceptable salts thereof obtained by the method according to any one of claims 3 to 6.

8. A glycosidase inhibitor, characterized in that The active ingredient of the glycosidase inhibitor comprises the fluorinated polyhydroxyindolizidine compound and a pharmaceutically acceptable salt thereof as claimed in any one of claims 1, 2 and 7.

9. Use of the glycosidase inhibitor according to claim 8 in inhibiting glycosidase, Preferably, the glycosidase is at least one selected from the group consisting of α-glucosidase, β-glucosidase, α-galactosidase, β-galactosidase, α-mannosidase, β-mannosidase, α-L-fucosidase, α,α-trehalase, α-L-rhamnosidase, amyloglucosidase and β-glucuronidase.

10. Use of the glycosidase inhibitor according to claim 9 in the preparation of a drug; Preferably, the drug is selected from at least one of the following drugs: drugs for preventing and / or treating diabetes; drugs for preventing and / or treating Gaucher's disease; drugs for preventing and / or treating tumors; antiviral drugs; antibacterial drugs; and drugs for preventing and / or treating Pompe disease.